ascopubs.org

Adjuvant radiation therapy in patients with breast cancer and Li-Fraumeni syndrome: Oncologic results and incidence of second neoplasms.

Tamoxifen induced ovarian hyperstimulation during hormonal therapy for breast cancer. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This abstract does not include a full text ...
ascopubs.org

Cost and Survival Analysis Before and After Implementation of Dana-Farber Clinical Pathways for Patients With Stage IV Non–Small-Cell Lung Cancer

Reducing Overuse of Colony-Stimulating Factors in Patients With Lung Cancer Receiving Chemotherapy: Evidence From a Decision Support–Enabled Program We created customized lung cancer pathways and ...
ascopubs.org

Avelumab-cetuximab-radiotherapy (RT) versus standards of care (SoC) in locally advanced squamous cell carcinoma of the head and neck (SCCHN): Safety phase of the randomized ...

Suboptimal regimens in sequential treatment (ST) with ICT (induction chemotherapy) followed by CCRT (concomitant chemotherapy) in "real life" patients with locally advanced pharyngo-laryngeal squamous ...
ascopubs.org

ASCO Clinical Practice Guidelines

Clinical practice guidelines serve as a guide for doctors and outline appropriate methods of treatment and care. Guidelines can address specific clinical situations (disease-oriented) or use of ...
ascopubs.org

Response to salvage chemotherapy following exposure to immune checkpoint inhibitors in patients with non-small cell lung cancer.

Response to single-agent (SA) chemotherapy (CTx) after immunotherapy exposure in non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract ...
ascopubs.org

NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non ...

Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA ...